HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

zanolimumab

a human monoclonal antibody targeted against CD4 for the potential treatment of cutaneous and noncutaneous T-cell lymphomas

Also Known As:

MDX-016; humax-CD4

Networked: 10 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Osterborg, Anders: 2 articles (09/2010 - 06/2007)
2.	Assaf, Chalid: 2 articles (12/2008 - 04/2007)
3.	Sterry, Wolfram: 2 articles (12/2008 - 04/2007)
4.	Parren, Paul W H I: 2 articles (10/2008 - 10/2007)
5.	Baadsgaard, Ole: 2 articles (10/2007 - 06/2007)
6.	Bayés, M: 2 articles (01/2006 - 06/2005)
7.	Prous, J R: 2 articles (01/2006 - 06/2005)
8.	Rabasseda, X: 2 articles (01/2006 - 06/2005)
9.	Brown, Nick: 1 article (05/2011)
10.	Illidge, Tim M: 1 article (05/2011)

Related Diseases

1.	T-Cell Lymphoma (Lymphoma, T Cell) 04/01/2007 - "Merck Serono SA, under license from Genmab A/S and Medarex Inc, is developing zanolimumab, a human mAb targeted against CD4, for the potential treatment of cutaneous (CTCL) and noncutaneous (NCTCL) T-cell lymphomas. " 10/15/2007 - "Zanolimumab is a human IgG1 antibody against CD4, which is in clinical development for the treatment of cutaneous and nodal T-cell lymphomas. " 09/01/2010 - "Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. " 05/01/2011 - "In addition emerging novel therapies including antibody drug conjugates (brentuximab vedotin, SGN-35) and mAb against T-cell lymphomas antigens (e.g., zanolimumab) offer hope of improved outcome for other lymphomas. "
2.	Neoplasms (Cancer) 10/01/2008 - "We depict how our science-based approach can be used to further improve the efficacy of antibody therapeutics, illustrated by the development of three monoclonal antibodies for various cancer indications: zanolimumab (directed against CD4), ofatumumab (directed against CD20) and zalutumumab (directed against epidermal growth factor receptor)."
3.	Lymphoma (Lymphomas) 05/01/2011 - "In addition emerging novel therapies including antibody drug conjugates (brentuximab vedotin, SGN-35) and mAb against T-cell lymphomas antigens (e.g., zanolimumab) offer hope of improved outcome for other lymphomas. "
4.	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 09/01/2010 - "Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. "
5.	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 09/01/2010 - "Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma." 09/01/2010 - "The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	ErbB Receptors (EGF Receptor)
3.	Immunoconjugates (Immunoconjugate)
4.	Hepatitis B e Antigens
5.	Brentuximab Vedotin
6.	zalutumumab
7.	ofatumumab
8.	Voriconazole (Vfend)
9.	Vaccines
10.	Sodium Oxybate (gamma Hydroxybutyrate)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Infusions